News

Japan’s Astellas Pharma has a US patent on Flomax, which is used for the treatment of benign prostatic hyperplasia, until October 27, 2009. Astellas, and Boehringer Ingelheim of

This breakthrough could eventually lead to revolutionary advances in the treatment of neurodegenerative illnesses such as Parkinson’s disease. The researchers used skin obtained from plastic surgery procedures. They

Men receiving AS1404 plus standard docetaxel chemotherapy had a substantially higher PSA response rate than men receiving chemotherapy alone. As previously reported, among the first 64 of 74

The phase III study, involving nearly 1,000 patients, achieved its co-primary endpoint – the inhibition of progression of structural damage. The trial also showed that in both active

The first milestone was completion of pharmacokinetic studies of the CureDM Human proIslet Peptide (HIP) in serum. These studies were important for defining structural improvements that stabilize the

Cesamet, a synthetic cannabinoid, was launched by Valeant in the US in 2006 for the treatment of nausea and vomiting associated with cancer chemotherapy in patients who have

The FDA has asked Genentech to revise the Xolair label and provide a medication guide for patients to strengthen the existing warning for anaphylaxis, a serious reaction which

TorreyPines said under the agreement, which began in February 2005, Eisai has exclusive rights of first negotiation and refusal for validated compounds that are discovered through the research.

Roche said Avastin's benefit was seen in patients who received either one of two different Avastin doses investigated in the new phase III trial. Roche explained the results